Effects of GABAA Receptor Modulation by AP-325 on Insulin Secretion in Patients With Type 2 Diabetes
Status:
Not yet recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
The aim of this single-center, prospective, randomized, double-blind, placebo-controlled,
2-arm parallel-group interventional study is to investigate the effect of 4-week treatment
with AP-325 on C-peptide release as measure of insulin secretion compared to placebo in type
2 diabetes (T2D) patients.
Phase:
Phase 2
Details
Lead Sponsor:
The Deutsche Diabetes Forschungsgesellschaft e.V.
Collaborator:
komIT - Center of Competence for Innovative Diabetes Therapy